Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine [Yahoo! Finance]
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
Gossamer Bio Decline Means Insider Profits Down To US$17k [Yahoo! Finance]
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.